Discovery of a Potent, Selective, Orally Bioavailable, and Efficacious Novel 2-(Pyrazol-4-ylamino)-pyrimidine Inhibitor of the Insulin-like Growth Factor-1 Receptor (IGF-1R).

Optimization of cellular lipophilic ligand efficiency (LLE) in a series of 2-anilino-pyrimidine IGF-1R kinase inhibitors led to the identification of novel 2-(pyrazol-4-ylamino)-pyrimidines with improved physicochemical properties. Replacement of the imidazo[1,2-a]pyridine group of the previously reported inhibitor 3 with the related pyrazolo[1,5-a]pyridine improved IGF-1R cellular potency. Substitution of the amino-pyrazole group was key to obtaining excellent kinase selectivity and pharmacokinetic parameters suitable for oral dosing, which led to the discovery of (2R)-1-[4-(4-{[5-chloro-4-(pyrazolo[1,5-a]pyridin-3-yl)-2-pyrimidinyl]amino}-3,5-dimethyl-1H-pyrazol-1-yl)-1-piperidinyl]-2-hydroxy-1-propanone (AZD9362, 28), a novel, efficacious inhibitor of IGF-1R.

[1]  R. Ducray,et al.  Novel imidazo[1,2-a]pyridine based inhibitors of the IGF-1 receptor tyrosine kinase: optimization of the aniline. , 2011, Bioorganic & medicinal chemistry letters.

[2]  Anders Poulsen,et al.  Discovery of the macrocycle 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a potent Janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) inhibitor for the treatment of myelofibrosis and lympho , 2011, Journal of medicinal chemistry.

[3]  Ken Grime,et al.  Use of Hepatocytes to Assess the Contribution of Hepatic Uptake to Clearance in Vivo , 2007, Drug Metabolism and Disposition.

[4]  N. Gibson,et al.  Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-1 receptor and insulin receptor. , 2009, Future medicinal chemistry.

[5]  S. Brewster,et al.  Silencing of the IGF1R gene enhances sensitivity to DNA-damaging agents in both PTEN wild-type and mutant human prostate cancer , 2005, Cancer Gene Therapy.

[6]  A. Hopkins,et al.  The role of ligand efficiency metrics in drug discovery , 2014, Nature Reviews Drug Discovery.

[7]  M. Barbacid,et al.  Cell cycle, CDKs and cancer: a changing paradigm , 2009, Nature Reviews Cancer.

[8]  D. M. Andrews,et al.  The discovery of AZD5597, a potent imidazole pyrimidine amide CDK inhibitor suitable for intravenous dosing. , 2008, Bioorganic & medicinal chemistry letters.

[9]  G. Trainor,et al.  Discovery of a 2,4-disubstituted pyrrolo[1,2-f][1,2,4]triazine inhibitor (BMS-754807) of insulin-like growth factor receptor (IGF-1R) kinase in clinical development. , 2009, Journal of medicinal chemistry.

[10]  David Buttar,et al.  A combined spectroscopic and crystallographic approach to probing drug-human serum albumin interactions. , 2010, Bioorganic & medicinal chemistry.

[11]  Brian J. Wilson,et al.  Discovery and optimization of imidazo[1,2-a]pyridine inhibitors of insulin-like growth factor-1 receptor (IGF-1R). , 2009, Bioorganic & medicinal chemistry letters.

[12]  J. Zha,et al.  Targeting the Insulin-like Growth Factor Receptor-1R Pathway for Cancer Therapy , 2010, Clinical Cancer Research.

[13]  Peter Ballard,et al.  Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor. , 2014, Journal of medicinal chemistry.

[14]  J. Nissink,et al.  Discovery of novel imidazo[1,2-a]pyridines as inhibitors of the insulin-like growth factor-1 receptor tyrosine kinase. , 2011, Bioorganic & medicinal chemistry letters.